Actively Recruiting
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Led by Neurocrine Biosciences · Updated on 2026-03-20
6
Participants Needed
3
Research Sites
209 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).
CONDITIONS
Official Title
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be a female or male between 0 to <2 years of age at screening.
- Have a medically confirmed diagnosis of classic CAH (salt wasting or simple virilizing) due to 21-hydroxylase deficiency.
- Be on a clinically stable regimen of hydrocortisone (and fludrocortisone, if applicable) treatment.
You will not qualify if you...
- Have a known or suspected diagnosis of any other forms of classic CAH.
- Have any condition besides CAH that requires chronic daily therapy with orally administered steroids.
- Have any other clinically significant medical condition or chronic disease.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Neurocrine Clinical Site
Berlin, Germany, 13353
Actively Recruiting
2
Neurocrine Clinical Site
Düsseldorf, Germany, 40225
Actively Recruiting
3
Neurocrine Clinical Site
Heidelberg, Germany, 69120
Actively Recruiting
Research Team
N
Neurocrine Medical Information Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here